<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879190</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03192009-2018</org_study_id>
    <secondary_id>15562</secondary_id>
    <nct_id>NCT00879190</nct_id>
  </id_info>
  <brief_title>Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis</brief_title>
  <official_title>Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters)
      surrounding the baby inside of a pregnant woman prior to delivery. This infection is somewhat
      common and is routinely treated with antibiotics given to the mother both before and after
      the baby is born. Currently it is not known what is the best choice of antibiotics to treat
      this type of infection, but commonly used treatments include Unasyn (ampicillin/sulbactam) or
      ampicillin/gentamicin. We plan to compare these two different antibiotic regimens to see if
      one is better than the other at treating and preventing bad outcomes from chorioamnionitis in
      women and babies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet inclusion criteria will be approached upon admission to Labor and Delivery.
      A study staff member will describe the study and offer participation. If a patient agrees to
      participate, she will sign research protocol and HIPAA consent forms and receive a copy of
      these forms. The patient's chart will be flagged, indicating that she is a study participant.
      The patient's prenatal care and labor and delivery will be managed by her physician per
      standard of care at the physician's discretion, including routine intrapartum treatment of
      Group B streptococcus (GBS) colonization using ampicillin. When a participating patient is
      diagnosed with chorioamnionitis, she will be randomized in a blinded fashion to Arm 1
      (Unasyn) or Arm 2 (ampicillin/gentamicin). She will be treated as per standard of care with
      tylenol, intravenous fluids, and her labor managed per physician discretion. From the time of
      diagnosis of chorioamnionitis until determination of treatment success or failure in the
      postpartum period, the patient will receive intravenous antibiotics per the protocol arm to
      which they have been assigned. If a patient has already been receiving ampicillin for GBS,
      the ampicillin will be discontinued when the study drugs are initiated. In arm 1, the study
      drugs will consist of Unasyn 3 grams intravenously every 6 hours, plus intravenous normal
      saline placebo dose every 8 hours. In arm 2, the study drugs will consist of gentamicin
      1.5mg/kg intravenously every 8 hours plus ampicillin 2gm intravenously every 6 hours. For all
      patients, clindamycin will be given intravenously at the time of clamping of the umbilical
      cord in the event of a cesarean delivery, and continued as part of the antibiotic regimen as
      per standard of care for cesarean section in the setting of chorioamnionitis. With the
      exception of the saline placebo doses, both the Unasyn regimen and the ampicillin/gentamicin
      regimen are efficacious and widely utilized regimens for the treatment of intrapartum
      chorioamnionitis, and do not represent a deviation from standard of care. After delivery, if
      the patient experiences a treatment failure as defined below, her medical care will be
      managed at the discretion of the attending physician as per standard of care, and her
      antibiotic regimen will be unblinded. After delivery, prior to discharge from the hospital,
      the patient will be asked to answer a short questionnaire enquiring about side effects
      experienced during treatment for chorioamnionitis. The patient may receive a phone call
      within 14 days of delivery to assess whether she has received treatment for postpartum
      complications at an outside institution after discharge from the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum</measure>
    <time_frame>Up to 24 hours after delivery</time_frame>
    <description>Proportion of patients in each arm experiencing treatment success defined as resolution of fever by 24 hours postpartum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Maternal Morbidity</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Composite of maternal postpartum morbidity defined as any of the following outcomes: endometritis, clinical sepsis, pneumonia, blood transfusion or ileus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Clinical Sepsis (Early Onset)</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Chorioamnionitis</condition>
  <arm_group>
    <arm_group_label>Unasyn (ampicillin/sulbactam)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ampicillin/gentamicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unasyn</intervention_name>
    <description>Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
    <arm_group_label>Unasyn (ampicillin/sulbactam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin/gentamicin</intervention_name>
    <description>Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
    <arm_group_label>Ampicillin/gentamicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women in labor or undergoing induction of labor

          2. Greater than or equal to 18 years of age

          3. Diagnosed with chorioamnionitis as defined by maternal temperature &gt; or = 38.0 degrees
             Centigrade plus at least one of the following: maternal tachycardia (heart rate &gt;110),
             fetal tachycardia (fetal heart rate baseline &gt;160), purulent amniotic fluid, uterine
             tenderness.

        Exclusion Criteria:

          1. Allergy or adverse reaction to penicillin or ampicillin, gentamicin, or sulbactam

          2. Having received antibiotics for the treatment of preterm premature rupture of
             membranes or other condition within the last 7 days

          3. Acute or chronic renal disease or insufficiency (creatinine &gt;1.0)

          4. Hearing loss

          5. Major fetal congenital anomalies or intrauterine fetal demise

          6. Neutropenia

          7. HIV

          8. Myasthenia gravis or other neuromuscular disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natali Aziz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.ajog.2014.10.310</url>
    <description>Comparison of ampicillin/sulbactam versus ampicillin/gentamicin for treatment of intrapartum chorioamnionitis: a randomized controlled trial</description>
  </link>
  <results_reference>
    <citation>Greenberg, Mara et al. Comparison of ampicillin/sulbactam versus ampicillin/gentamicin for treatment of intrapartum chorioamnionitis: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology , Volume 212 , Issue 1 , S145</citation>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Natali Aziz</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorioamnionitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unasyn (Ampicillin/Sulbactam)</title>
          <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
        </group>
        <group group_id="P2">
          <title>Ampicillin/Gentamicin</title>
          <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unasyn (Ampicillin/Sulbactam)</title>
          <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
        </group>
        <group group_id="B2">
          <title>Ampicillin/Gentamicin</title>
          <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="7.1"/>
                    <measurement group_id="B2" value="28.3" spread="5.6"/>
                    <measurement group_id="B3" value="28.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nulliparous</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal pre-existing comorbidity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum</title>
        <description>Proportion of patients in each arm experiencing treatment success defined as resolution of fever by 24 hours postpartum</description>
        <time_frame>Up to 24 hours after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unasyn (Ampicillin/Sulbactam)</title>
            <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
          </group>
          <group group_id="O2">
            <title>Ampicillin/Gentamicin</title>
            <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum</title>
          <description>Proportion of patients in each arm experiencing treatment success defined as resolution of fever by 24 hours postpartum</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Maternal Morbidity</title>
        <description>Composite of maternal postpartum morbidity defined as any of the following outcomes: endometritis, clinical sepsis, pneumonia, blood transfusion or ileus.</description>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unasyn (Ampicillin/Sulbactam)</title>
            <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
          </group>
          <group group_id="O2">
            <title>Ampicillin/Gentamicin</title>
            <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Maternal Morbidity</title>
          <description>Composite of maternal postpartum morbidity defined as any of the following outcomes: endometritis, clinical sepsis, pneumonia, blood transfusion or ileus.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Clinical Sepsis (Early Onset)</title>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unasyn (Ampicillin/Sulbactam)</title>
            <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
          </group>
          <group group_id="O2">
            <title>Ampicillin/Gentamicin</title>
            <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Clinical Sepsis (Early Onset)</title>
          <units>affected neonates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 6 weeks after delivery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Unasyn (Ampicillin/Sulbactam)</title>
          <description>Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.</description>
        </group>
        <group group_id="E2">
          <title>Ampicillin/Gentamicin</title>
          <description>Ampicillin/gentamicin: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postpartum endometritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Girsen, Manager of Maternal-Fetal Medicine Research Operations</name_or_title>
      <organization>Stanford University, Department of Obstetrics &amp; Gynecology</organization>
      <phone>(650) 725-0499</phone>
      <email>agirsen@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

